The Biopsy Devices Market is experiencing steady expansion as healthcare systems place greater emphasis on early disease detection, minimally invasive diagnosis, and accurate tissue sampling. Biopsy devices are essential tools used to obtain tissue or cell samples for pathological examination, particularly in cancer diagnosis and staging. According to Market Research Future, the global market was valued at approximately USD 2.40 billion in 2025 and is projected to reach USD 3.65 billion by 2035, registering a CAGR of 4.30% during the forecast period. The increasing incidence of cancer worldwide is a major factor supporting demand for biopsy procedures. Breast, lung, prostate, liver, and gynecological conditions frequently require tissue confirmation before treatment decisions can be finalized. Advances in imaging-guided procedures are also improving the precision and safety of tissue collection. Ultrasound, CT, MRI, and stereotactic guidance technologies are increasingly being integrated with biopsy systems, helping clinicians target suspicious lesions more accurately. Needle-based biopsy instruments accounted for 47.5% of market revenue in 2025, demonstrating the continued importance of core and vacuum-assisted systems. Breast biopsy represented the largest application segment, with a 33.4% share, while lung biopsy is expected to record particularly strong growth as lung-cancer screening programs expand.

North America currently dominates the industry, accounting for approximately 44.1% of global revenue in 2025, supported by high screening rates, established healthcare infrastructure, and broad availability of image-guided diagnostic services. Asia-Pacific is expected to be the fastest-growing regional market, with a projected CAGR of 8.90% through 2035, driven by healthcare infrastructure development, increasing cancer screening, and expanding access to advanced diagnostic technologies. Hospitals remain the largest end users, while ambulatory surgical centers and diagnostic imaging facilities are gaining importance as healthcare delivery increasingly shifts toward outpatient settings. Key participants include BD, Hologic, Medtronic, Merit Medical Systems, Boston Scientific, Cardinal Health, Cook Medical, Argon Medical Devices, Stryker, and Leica Biosystems. Manufacturers are focusing on disposable biopsy instruments, improved needle designs, automated sampling, AI-assisted image guidance, and integrated digital workflows. High equipment costs, regulatory requirements, procedural complexity, and the need for trained healthcare professionals remain challenges. Nevertheless, growing cancer screening programs, minimally invasive procedures, AI-enabled guidance, and expanding diagnostic infrastructure are expected to sustain Market Growth through 2035.